These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 6459224)

  • 21. Antimicrobial activity and spectrum of cefoperazone against recent clinical isolates.
    Jones RN; Fuchs PC; Barry AL; Gavan TL; Gerlach EH; Sommers HM
    Clin Ther; 1980; 3(Spec Issue):14-23. PubMed ID: 6446389
    [No Abstract]   [Full Text] [Related]  

  • 22. [Experimental and clinical studies on cefoperazone (author's transl)].
    Toyonaga Y; Kurosu Y; Yoshikawa H; Kumagai K; Takahashi T; Hori M
    Jpn J Antibiot; 1980 Aug; 33(8):820-40. PubMed ID: 6451729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefmenoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Campoli-Richards DM; Todd PA
    Drugs; 1987 Aug; 34(2):188-221. PubMed ID: 3304966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activity of cefoperazone-sulbactam: Singapore experience.
    Kumarasinghe G; Chow C; Chiu C; Cheong YM
    Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):734-7. PubMed ID: 9253876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum beta-lactam antibiotic.
    Neu HC
    Ther Drug Monit; 1981; 3(2):121-8. PubMed ID: 6455787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Minimal inhibitory and bactericidal concentrations of cefoperazone, cefotaxime, cefuroxime and cefalotin against 90 bacterial strains].
    Mascellino MT; Prignano G; Iegri F; Lorenzi A
    Boll Ist Sieroter Milan; 1982; 61(4):309-19. PubMed ID: 6100234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental efficacy and pharmacokinetic properties of cefpiramide, a new cephalosporin.
    Fu KP; Vince T; McCloud S; Gregory FJ; Chiang ST; Hung PP
    Drugs Exp Clin Res; 1985; 11(11):787-91. PubMed ID: 3939215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro evaluation of cefoperazone.
    Hinkle AM; LeBlanc BM; Bodey GP
    Antimicrob Agents Chemother; 1980 Mar; 17(3):423-7. PubMed ID: 6448578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review.
    Garzone P; Lyon J; Yu VL
    Drug Intell Clin Pharm; 1983; 17(7-8):507-15. PubMed ID: 6347596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetics of a new cephalosporin, cefoperazone].
    Allaz AF; Dayer P; Fabre J; Rudhardt M; Balant L
    Schweiz Med Wochenschr; 1979 Dec; 109(50):1999-2005. PubMed ID: 538442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [In vitro antibacterial activity of cefodizime (HR 221) on 323 hospital strains of Gram negative bacilli. Comparison with cefotiam, cefoperazone, cefotetan and cefotaxime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1985 May; 33(5):399-403. PubMed ID: 3897972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibacterial properties of Ro 13-99041, a long-acting new cephalosporin.
    Angehrn P; Probst PJ
    Chemotherapy; 1981; 27 Suppl 1():9-14. PubMed ID: 7249797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The selection and use of cephalosporins: a review.
    Klein NC; Cunha BA
    Adv Ther; 1995; 12(2):83-101. PubMed ID: 10150326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Richards DM; Brogden RN
    Drugs; 1985 Feb; 29(2):105-61. PubMed ID: 3884319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aztreonam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Brogden RN; Heel RC
    Drugs; 1986 Feb; 31(2):96-130. PubMed ID: 3512234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Third-generation cephalosporins: comparative antibacterial activity against routine clinical isolates.
    Corser CA; Day GJ; Humble MW
    N Z Med J; 1982 Jun; 95(710):414-6. PubMed ID: 6810246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Review of oral cephalosporins. Basis for a rational choice].
    Forti IN
    Medicina (B Aires); 1994; 54(5 Pt 1):439-58. PubMed ID: 7658980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Laboratory and clinical studies on cefoperazone in pediatrics treatment (author's transl)].
    Motohiro T; Takechi T; Soejima N; Watari H; Oohashi K; Sakata Y; Nishiyama T; Ezaki Y; Yokoyama T; Nakajima T; Komatsu Y; Ishimoto K; Tominaga K; Yamashita F; Takeya S; Yamamoto M; Ohkita R; Iriki T
    Jpn J Antibiot; 1980 Sep; 33(9):943-58. PubMed ID: 6452544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gram-negative bacterial toe web infection: successful treatment with a new third generation cephalosporin.
    Eaglstein NF; Marley WM; Marley NF; Rosenberg EW; Hernandez AD
    J Am Acad Dermatol; 1983 Feb; 8(2):225-8. PubMed ID: 6219139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
    Perry CM; Scott LJ
    Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.